CoChat

Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma

Open access

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

BACKGROUND: While cancer immunotherapies including checkpoint blockade antibodies, adoptive T cell therapy, and even some vaccines have given rise to major clinical responses with durability in many cases, a subset of patients who initially respond subsequently develop secondary resistance to therapy. Tumor-intrinsic mechanisms of acquired immunotherapy resistance are incompletely understood. METHODS: Baseline and treatment-resistant tumors underwent molecular analysis via transcriptional profiling or genomic sequencing for oncogenic alterations and histologic analysis for T cell infiltration to investigate mechanisms contributing to T cell exclusion and acquired resistance to immunotherapy. RESULTS: We describe two patients with metastatic melanoma who initially showed a durable partial response to either a melanoma-peptide/interleukin-12 vaccine or combined anti-CTLA-4 + anti-PD-1 therapy, but subsequently developed new treatment-resistant metastases. In the first case, the recurrent tumor showed new robust tumor expression of β-catenin, whereas in the second case genomic sequencing revealed acquired PTEN loss. Both cases were associated with loss of T cell infiltration, and both pathways have been mechanistically linked to immune resistance preclinically. CONCLUSION: Our results suggest that secondary resistance to immunotherapies can arise upon selection for new oncogenic variants that mediate T cell exclusion. To identify the spectrum of underlying mechanisms of therapeutic resistance, similar evaluation for the emergence of tumor-intrinsic alterations in resistant lesions should be done prospectively at the time of relapse in a range of additional patients developing secondary resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-019-0780-0

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Tumor gene expression profiling, CD8+ T cell infiltration, and β-catenin status at baseline and at recurrence. a Immunohistochemistry staining for CD8 (red staining) and β-catenin (red staining), in baseline (pre-treatment, right lower paratracheal lymph node metastasis) and recurrent (treatment-resistant, left inguinal lymph node metastasis) melanoma tumor biopsies. b Expression level of immune-related genes in baseline and recurrent tumor samples measured by genome expression microarray. Depicted are the genes GZMK, CD8A, CCL4, CXCL9, CCL3, CCL5, HLADMA, CXCL10, TRGC2, TRAA, NKG7, CD2, TRGV9, TRGC2, PRF1, CD8B, TRBC1, CD38, IL1R2, IL23A, TRBC1, IL2RG, CCL18, CD27, IFNG, RAC2, TNFSF10, CD3E, TAP1, TNFRSF9, HLADPA1, TAP2, NLRP1, STAT1, CXCL13. Genes in bold font are being shown in red and were previously part of our core signature associated with CD8+ T cells [21]. c Gene expression levels of six β-catenin target genes (VEGFA, TCF12, MYC, TCF1, EFNB3, APC2) as well as β-catenin (CTNNB1, red) itself. Genome microarray data (b and c): expression levels for each gene transcript are normalized to median signal intensity of all genes on the microarray, and represented as normalized hybridization intensity data and expressed as expression units
Fig. 1 Tumor gene expression profiling, CD8+ T cell infiltration, and β-catenin status at baseline and at recurrence. a Immunohistochemistry staining for CD8 (red staining) and β-catenin (red staining), in baseline (pre-treatment, right lower paratracheal lymph node metastasis) and recurrent (treatment-resistant, left inguinal lymph node metastasis) melanoma tumor biopsies. b Expression level of immune-related genes in baseline and recurrent tumor samples measured by genome expression microarray. Depicted are the genes GZMK, CD8A, CCL4, CXCL9, CCL3, CCL5, HLADMA, CXCL10, TRGC2, TRAA, NKG7, CD2, TRGV9, TRGC2, PRF1, CD8B, TRBC1, CD38, IL1R2, IL23A, TRBC1, IL2RG, CCL18, CD27, IFNG, RAC2, TNFSF10, CD3E, TAP1, TNFRSF9, HLADPA1, TAP2, NLRP1, STAT1, CXCL13. Genes in bold font are being shown in red and were previously part of our core signature associated with CD8+ T cells [21]. c Gene expression levels of six β-catenin target genes (VEGFA, TCF12, MYC, TCF1, EFNB3, APC2) as well as β-catenin (CTNNB1, red) itself. Genome microarray data (b and c): expression levels for each gene transcript are normalized to median signal intensity of all genes on the microarray, and represented as normalized hybridization intensity data and expressed as expression unitsCC BY · PubMed Central
Fig. 2 Peripheral tumor-reactive T cells persist at the time of progression. a Expression-level of targeted tumor antigens in pre-treatment (unfilled bars) and resistant (filled bars) tumor samples determined by genome expression microarray (NA-17 not represented on the gene array). Gene expression of targeted antigen transcripts are normalized to median signal intensity of all genes on the array and expressed as expression units. b IFN-γ ELISpot assessing the T cell reactivity against the four peptides used in the vaccine, gp100, Melan-A, MAGE-3, NA-17, over time during initial treatment. PBMCs isolated at each time point and stimulated with the indicated melanoma peptides or media control. Samples analyzed in triplicate and presented as the mean number of spots per number of PBMCs with standard deviation. Mean number of spots for each peptide compared to media control. P-values for gp100, Melan-A, MAGE-3, and NA17 peptide versus media control listed from top to bottom, respectively, at each time point, *p < 0.05, **p < 0.001, ***p < 000.1 (c) IFN-γ ELISpot showing persistent T cell reactivity against three melanoma peptides (gp100, Melan-A and MAGE-3) at the time of progression. PBMCs stimulated with media control, EBV antigen (control peptide), gp100, Melan-A, MAGE-3, and NA17 peptide. Samples analyzed in triplicate and presented as the mean number of spots per number of PBMCs with standard deviation. Mean number of spots compared to media control. *p < 0.05, **p < 0.001, ***p < 000.1
Fig. 2 Peripheral tumor-reactive T cells persist at the time of progression. a Expression-level of targeted tumor antigens in pre-treatment (unfilled bars) and resistant (filled bars) tumor samples determined by genome expression microarray (NA-17 not represented on the gene array). Gene expression of targeted antigen transcripts are normalized to median signal intensity of all genes on the array and expressed as expression units. b IFN-γ ELISpot assessing the T cell reactivity against the four peptides used in the vaccine, gp100, Melan-A, MAGE-3, NA-17, over time during initial treatment. PBMCs isolated at each time point and stimulated with the indicated melanoma peptides or media control. Samples analyzed in triplicate and presented as the mean number of spots per number of PBMCs with standard deviation. Mean number of spots for each peptide compared to media control. P-values for gp100, Melan-A, MAGE-3, and NA17 peptide versus media control listed from top to bottom, respectively, at each time point, *p < 0.05, **p < 0.001, ***p < 000.1 (c) IFN-γ ELISpot showing persistent T cell reactivity against three melanoma peptides (gp100, Melan-A and MAGE-3) at the time of progression. PBMCs stimulated with media control, EBV antigen (control peptide), gp100, Melan-A, MAGE-3, and NA17 peptide. Samples analyzed in triplicate and presented as the mean number of spots per number of PBMCs with standard deviation. Mean number of spots compared to media control. *p < 0.05, **p < 0.001, ***p < 000.1CC BY · PubMed Central
Fig. 3 Acquired genetic loss of PTEN in a therapy-resistant melanoma tumor in a patient previously responding to ant-CTLA-4 and anti-PD-1 therapy. a and b Copy number alterations. Next generation sequencing of pre-treatment and therapeutic-resistant melanoma lesions shows acquired loss of PTEN in the treatment resistant tumor specimen but not the pre-treatment lesion. Log2 of fold- changes in the (a) pre-treatment tumor sample (upper panel) and (b) treatment-resistant metastasis (lower panel). The analysis shows copy number changes in BRAF, PTEN, CDKN2A, FANCA, H3F3A, NOTCH1, PALB2, RAD51, RET, TSC1, TSC2. Copy number alterations are indicated in red. Genomic regions across the chromosomes that have no detectable alterations are indicated in blue or gray. Dotted lines indicate the Log2 fold-change cutoffs
Fig. 3 Acquired genetic loss of PTEN in a therapy-resistant melanoma tumor in a patient previously responding to ant-CTLA-4 and anti-PD-1 therapy. a and b Copy number alterations. Next generation sequencing of pre-treatment and therapeutic-resistant melanoma lesions shows acquired loss of PTEN in the treatment resistant tumor specimen but not the pre-treatment lesion. Log2 of fold- changes in the (a) pre-treatment tumor sample (upper panel) and (b) treatment-resistant metastasis (lower panel). The analysis shows copy number changes in BRAF, PTEN, CDKN2A, FANCA, H3F3A, NOTCH1, PALB2, RAD51, RET, TSC1, TSC2. Copy number alterations are indicated in red. Genomic regions across the chromosomes that have no detectable alterations are indicated in blue or gray. Dotted lines indicate the Log2 fold-change cutoffsCC BY · PubMed Central
Fig. 4 Loss of PTEN protein expression by melanoma cells associated with a lack of CD8+ T cell infiltration. a Immunofluorescence demonstrates that the on-treatment specimen shows PTEN protein expression by SOX10-positive melanoma cells and CD8+ T cell infiltration (left panels); (b) the therapeutic-resistant post-treatment specimen (right panels) from the same patient shows minimal PTEN protein expression by SOX10-positive melanoma cells and no CD8+ T cell infiltration. Multiplex immunofluorescence staining was performed for DAPI, Sox10, CD8, and PTEN; each stain shown separately and merged
Fig. 4 Loss of PTEN protein expression by melanoma cells associated with a lack of CD8+ T cell infiltration. a Immunofluorescence demonstrates that the on-treatment specimen shows PTEN protein expression by SOX10-positive melanoma cells and CD8+ T cell infiltration (left panels); (b) the therapeutic-resistant post-treatment specimen (right panels) from the same patient shows minimal PTEN protein expression by SOX10-positive melanoma cells and no CD8+ T cell infiltration. Multiplex immunofluorescence staining was performed for DAPI, Sox10, CD8, and PTEN; each stain shown separately and mergedCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 185

Metadata

Authors
Trujillo, J. A., Luke, J. J., Zha, Y., Segal, J. P., Ritterhouse, L. L., Spranger, S., Matijevich, K., & Gajewski, T. F.
Affiliations
University of Chicago (US)
Corresponding author
Gajewski, Thomas F.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2019-11-08
Volume
7
Issue
1
Pages
295-295
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2983934251
Cited by
159
References
35
Citations by year
2026: 11 · 2025: 20 · 2024: 20 · 2023: 18 · 2022: 25 · 2021: 35 · 2020: 30
FWCI
10.22
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
Funders
  • National Institutes of Health (2T32CA009566-31)
  • National Cancer Institute (R00CA204595, R35CA210098)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
metastatic melanoma, PTEN loss, T-cell exclusion, anti-CTLA-4, anti-PD-1, adoptive T cell therapy, T cell infiltration
MeSH terms
Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Adult, Humans, Immunotherapy, Male, Melanoma, Middle Aged, Signal Transduction, Interleukin-12, Drug Resistance, Neoplasm, Cancer Vaccines, PTEN Phosphohydrolase, beta Catenin, Young Adult, High-Throughput Nucleotide Sequencing, Transcriptome, CTLA-4 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma. https://app.cochat.ai/papers/10.1186/s40425-019-0780-0
The paper
Trujillo, J. A., Luke, J. J., Zha, Y., Segal, J. P., Ritterhouse, L. L., Spranger, S., Matijevich, K., & Gajewski, T. F. (2019). Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-019-0780-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.